Trade Names:Crolom- Solution, ophthalmic 4%
Trade Names:Cromolyn sodium- Solution, inhalation 20 mg per 2 mL- Solution, ophthalmic 4%
Trade Names:Gastrocrom- Concentrate, oral 100 mg per 5 mL
Trade Names:Intal- Solution, inhalation 20 mg/amp- Aerosol inhalation 800 mcg/actuation
Trade Names:Nasalcrom- Solution, nasal 40 mg/mL (each actuation delivers 5.2 mg)Apo-Cromolyn (Canada)Cromolyn (Canada)Nalcrom (Canada)Opticrom (Canada)
Stabilizes mast cells, which release histamine and other mediators of allergic reactions.
8% absorbed from the lungs.Oral concentrate
Up to 1% absorbed.
After 8% is absorbed from the lung, it is rapidly excreted unchanged in bile and urine. The remainder is either exhaled or swallowed and excreted via the alimentary tract.Oral concentrate
0.28% to 0.5% of the dose is excreted in the urine.
Prophylactic agent for management of bronchial asthma.Nasal spray
Prevent and relieve nasal symptoms of hay fever and other nasal allergies, including runny/itchy nose, sneezing, and allergic stuffy nose.Oral concentrate
Treatment of mastocytosis.Ophthalmic
Treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.
Symptoms of food allergies; eczema; dermatitis; ulceration; urticaria pigmentosa; chronic urticaria; hay fever; and postexercise bronchospasm.
Nebulization Initially 20 mg inhaled 4 times daily at regular intervals.Adults and Children (older than 5 yr of age)
Aerosol 2 metered sprays (1,600 mcg) inhaled 4 times daily at regular intervals.MastocytosisAdults and Children 13 yr of age and older
PO 200 mg 4 times daily 30 min before meals and at bedtime. Once a therapeutic response has been achieved, dose may be reduced to minimum needed to maintain a lower degree of symptomatology. To prevent relapses, dosage should be maintained.Children 2 to 12 yr of age
PO 100 mg 4 times daily 30 min before meals and at bedtime. If satisfactory control of symptoms is not achieved within 2 to 3 wk, dosage may be increased (max, 40 mg/kg/day). Once a therapeutic response has been achieved, dose may be reduced to minimum needed to maintain a lower degree of symptomatology. To prevent relapses, dosage should be maintained.Nasal AllergyAdults and Children 2 yr of age and older
Nasal spray Spray once into each nostril; repeat 3 to 4 times daily (every 4 to 6 h up to 6 times/day) if needed.Prevention of Acute BronchospasmAdults
Nebulizer solution/aerosol 2 metered dose sprays or 20 mg via inhaled nebulizer (10 to 15 min but no longer than 60 min) before exposure to precipitating factor.Vernal Keratoconjunctivitis, Vernal Conjunctivitis, and Vernal KeratitisAdults
Ophthalmic solution 1 to 2 drops in each eye 4 to 6 times/day at regular intervals.
Store between 59° and 86°F. Do not puncture, incinerate, or place near heat sources.Nasal spray
Store between 68° and 77°F. Protect from light.Nebulizer solution
Store between 69° and 77°F. Protect from light.Ophthalmic solution
Store between 59° and 86°F. Protect from light. Keep tightly closed. Replace cap immediately after use.Oral concentrate
Store between 59° and 86°F. Protect from light.
None well documented.
None well documented.
Palpitations, premature ventricular contractions, tachycardia (postmarketing).
Dizziness, headache.Oral concentrate
Irritability, malaise; anxiety, behavior change, convulsions, depression, fatigue, hallucinations, hypoesthesia, insomnia, migraine, nervousness, paresthesia (postmarketing).Nebulizer solution
Rash, urticaria.Oral concentrate
Pruritus, rash; erythema/burning, flushing, photosensitivity, purpura, urticaria/angioedema (postmarketing).
Lacrimation, laryngeal edema, nasal congestion, pharyngeal irritation, swollen parotid gland, throat irritation or dryness.Nebulizer solution
Nasal congestion, nasal itching, nose burning, nosebleed, sneezing.Ophthalmic solution
Conjunctival injection, dryness around the eye, eye irritation, itchy eyes, ocular burning and stinging upon installation, puffy eyes, styes, watery eyes.Oral concentrate
Pharyngitis, tinnitus (postmarketing).
Bad taste, nausea, substernal burning.Nebulizer solution
Nausea, stomachache.Oral concentrate
Abdominal pain, diarrhea, nausea; constipation, dyspepsia, dysphagia, esophagospasm, flatulence, glossitis, stomatitis, vomiting (postmarketing).
Dysuria, urinary frequency.Oral concentrate
Dysuria, urinary frequency (postmarketing).
Neutropenia, pancytopenia, polycythemia (postmarketing).
Abnormal LFTs (postmarketing).
Joint swelling and pain, myopathy.Oral concentrate
Myalgia; arthralgia, stiffness/weakness of legs (postmarketing).
Bronchospasm, cough, pulmonary infiltrates with eosinophilia, wheezing.Nasal solution
Cough, wheezing.Oral concentrate
Anaphylaxis, angioedema.Nebulizer solution
Serum sickness.Ophthalmic solution
Immediate hypersensitivity (including edema, dyspnea, and rash)Oral concentrate
Chest pain, edema, lupus erythematosus syndrome, postprandial lightheadedness and lethargy (postmarketing).
Instruct patients to notify health care provider of the following: wheezing or coughing after inhalation or stinging effect after nasal instillation, joint pain, severe wheezing, difficulty breathing, chills, sweating, or chest pain, which may indicate eosinophilic pneumonia.Therapeutic efficacy
Evaluate therapeutic efficacy by decrease in frequency or severity of clinical symptoms or decrease in need for cotherapy over period of 4 wk.
Category B .
Safety and efficacy not established in children younger than 5 yr of age.Nebulizer solution
Safety and efficacy not established in children younger than 2 yr of age.Nasal spray
Do not use in children younger than 2 yr of age unless directed by health care provider.Ophthalmic solution
Safety and efficacy not established in children younger than 4 yr of age.Oral concentrate
Safety and efficacy not established in children younger than 2 yr of age.
Use with caution, usually starting at low end of dosage range, because of the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant diseases or other drug therapy.
Severe anaphylactic reactions may occur.
Decreased dose is recommended.
Decreased dose is recommended.
Do not use for acute asthma attack. Effects depend on regular administration.
Use with caution in patients with coronary artery disease or cardiac arrhythmias because of propellants in this preparation.
Cough or bronchospasm may follow inhalation.
If signs of this condition occur, therapy will need to be discontinued.
Copyright © 2009 Wolters Kluwer Health.